Which company does cimepilimab come from?

Cemiplimab is an innovative immunotherapy drug developed and produced by Regeneron Pharmaceuticals, Inc., with the trade name Libtayo. The drug was approved by the U.S. Food and Drug Administration (FDA) in 2018, becoming the first and only treatment option for patients with advanced cutaneous squamous cell carcinoma (CSCC). This approval not only marks a major breakthrough for Regeneron in the field of tumor immunotherapy, but also provides new hope for clinical treatment.

Cimepilimab, as a programmed death receptor-1 (PD-1) blocking antibody, enhances the body's immune response by targeting the PD-1 receptor. PD-1 is an important immune checkpoint. Under normal circumstances, it inhibits the activity of T cells by binding to its ligand, thereby regulating immune responses to prevent the occurrence of autoimmune diseases. However, many tumor cells exploit this mechanism to evade immune system attack. Cimepilimab blocks the binding of PD-1 to its ligands and relieves the inhibition of T cells, allowing the immune system to effectively recognize and kill tumor cells.

The clinical application of cimipilimab is not limited to advanced stage CSCC, but has also shown good efficacy in diseases such as basal cell carcinoma (BCC) and non-small cell lung cancer (NSCLC). The expansion of these indications further demonstrates the broad potential of cimepilimab in anti-tumor therapy. Compared with traditional treatment methods, the emergence of cimepilimab provides new treatment options for patients with refractory cancer and improves patients' survival rate and quality of life.

Regeneron Pharmaceuticals has a strong reputation in biopharmaceuticals and its R&D team is dedicated to developing breakthrough therapies to address unmet medical needs. Relying on its strong scientific research background and technology platform, the company continues to promote the research and development and launch of new drugs, and cimepilimab is one of its important achievements.

Reference materials:https://investor.regeneron.com/news-releases/news-release-details/fda-approves-libtayor-cemiplimab-rwlc-first-and-only-treatment/